ml9b00612_si_001.pdf (8.37 MB)
Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson’s Disease
journal contribution
posted on 2020-03-19, 11:35 authored by Thomas M. Kaiser, Zackery W. Dentmon, Christopher E. Dalloul, Savita K. Sharma, Dennis C. LiottaParkinson’s
disease (PD) is a debilitating and common neurodegenerative
disease. New insights implicating c-Abl activation as a driving force
in PD have opened a new drug development avenue for PD treatment beyond
the symptomatic relief by L-DOPA. BCR-Abl inhibitors, which include
nilotinib and ponatinib, have been found to inhibit this process,
and nilotinib has shown improvement in outcomes in a 12-patient, nonrandomized
trial. However, nilotinib is a potent inhibitor of hERG, a cardiac
K+ channel whose inhibition increases risk of sudden death.
We used our machine learning approach to predict novel molecules that
would inhibit c-Abl while also having minimal liability against hERG.
Of our six novel compounds tested, we identified two that had c-Abl
potencies comparable to nilotinib, but with significantly improved
profiles regarding the hERG channel. Our best compound exhibited a
hERG IC50 of 12.1 μM (compared to nilotinib with
an IC50 of 0.45 μM and ponatinib with IC50 of 0.767 μM). This work is a step forward for a machine learning
enabled, multiparameter optimization of a chemical space and represents
a significant advance in the development of novel Parkinson’s
therapies.